From dual peroxisome proliferator activated receptor agonists to selective peroxisome proliferator activated receptor modulators

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 2, Issue 1, 2008, Pages 24-28

  Dagdelen, Selcuk ^a,b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HACETTEPE UNIVERSITY   (Turkey)

^c NONE   (United Kingdom)

Author keywords

AMG131; Atherosclerosis; Dual PPAR agonists; FK614; FMOC L leucine; GW0072; Metabolic syndrome; nTZDpa; Peroxisome proliferator activated receptors; SPPARMs; Type 2 diabetes

Indexed keywords

5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; BEZAFIBRATE; CLOFIBRATE; FARGLITAZAR; FENOFIBRATE; GEMFIBROZIL; GLUCOSE; GW 625019; GW 766954; IMIGLITAZAR; LIPID; METAGLIDASEN; MURAGLITAZAR; NAVEGLITAZAR; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLX 204; RAGAGLITAZAR; RIVOGLITAZONE; ROSIGLITAZONE; SIPOGLITAZAR; TESAGLITAZAR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTHRALGIA; ATHEROSCLEROSIS; BONE MARROW SUPPRESSION; CARCINOGENICITY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DYSLIPIDEMIA; EDEMA; EPIDEMIC; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEADACHE; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PAIN; PATENT; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; RISK MANAGEMENT; SIDE EFFECT; TISSUE DISTRIBUTION; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 42149144739     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221408783421273     Document Type: Review

References (32)

1. Benoit G, Cooney A, Giguere V, et al. International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol Rev 2006; 58: 798-836.
2. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999; 354: 141-148.
3. Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ. Dual PPAR alpha/ gamma agonists: promises and pitfalls in type 2 diabetes. Am J Ther 2007; 14: 49-62.
4. Zavaroni I, Bonini L, Fantuzzi M, Dall'Aglio E, Passeri M, Reaven GM. Hyperinsulinaemia, obesity, and syndrome X. J Intern Med 1994; 235: 51-56.
5. Schwarz PE, Reiman M, Li J, et al. The metabolic syndrome - a global challenge for prevention. Horm Metab Res 2007; 39: 777-780.
6. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-342.
7. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005; 4: 14-16.
8. Giannini S, Serio M, Gali A. Pleitropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 2004; 27, 982-991.
9. Chang F, Jaber LA, Berlie HD, O'Connel MB. Evolution of peroxisome proliferator-activator receptor agonists. Ann Pharmacother 2007; 41, 973-983.
10. Kepez A, Oto A, Dagdelen S. Peroxisome proliferator-activated receptor-gamma: novel therapeutic target linking adiposity, insulin resistance, and atherosclerosis. BioDrugs 2006; 20: 121-135.
11. Normen L, Frohlich J, Montaner J, Harris M, Elliott T, Bondy G. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care 2004; 27: 2241-2242.
12. Seber S, Ucak S, Basat O, Altuntas Y. The effect of dual PPAR alpha/ gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clin Pract 2006; 71: 52-58.
13. Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologis 2007; 50: 1723-1731
14. Balakumar P, Rose M, Singh M. PPAR ligands: are they potential agents for cardiovascular disorders? Pharmacology 2007; 80: 177-184.
15. Shearer BG, Billin AN. The next generation of PPAR drugs: do we have the tools to find them? Biochim Biophys Acta 2007; 1771: 1082-1093.
16. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M. PPAR dual agonists: are they opening Pandora's Box? Pharmacol Res 2007; 56: 91-98.
17. Berg EL, Kunkel EJ, Hytopoulos E, Plavec I. Characterization of compound mechanisms and secondary activities by BioMAP analysis. J Pharmacol Toxicol Methods 2006; 53: 67-74.
18. Oberfield JL, Collins JL, Holmes CP, et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA 1999; 96: 6102-6106.
19. Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
20. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002; 143: 2376-2384.
21. Bishop-Bailey D, Warner TD. PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist. FASEB J 2003; 17: 1925-1927.
22. Rocchi S, Picard F, Vamecq J, et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 2001; 8: 731-747.
23. Koutnikova H, Auwerx J. PPAR gamma, an X-ceptor for Xs. Ann N Y Acad Sci 2002; 967: 28-33.
24. Berger JP, Petro AE, Macnaul KL, et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol 2003; 17: 662-676.
25. Bruemmer D, Berger JP, Liu J, et al. A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth. Eur J Pharmacol 2003; 466, 225-234.
26. Fujimura T, Sakuma H, Konishi S, et al. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. J Pharmacol Sci 2005; 99: 342-352.
27. Minoura H, Takeshita S, Yamamoto T, et al. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat. Eur J Pharmacol 2005; 519: 182-190.
28. Malecha, J.W., Lindstrom, A.K., Duron, S.G., Govek, S.P.: WO07047432 ( 2007).
29. Kalypsys, I., Zhao, C.: WO07109577 (2007).
30. Lin, J., Womack, P., Lee, B., Shi, S., Zhang, C., Zuckerman, R., Artis, D.R., Ibrahim, P.N., Wang, W.: WO07030559 (2007).
31. Malecha, J.W., Lindstrom, A.K., Duron, S.G., Thomas, D.J.: WO07047431 (2007).
32. Epple, R., Cow, C.: WO07089557 (2007).